期刊文献+

建立我国炎症性肠病诊治中心质量控制指标的共识 被引量:15

原文传递
导出
摘要 炎症性肠病(inflammatory boweldisease,IBD)主要包括溃疡性结肠炎(ulcerativecolitis,UC)和克罗恩病(Crohn’s disease,CD)。近年来IBD的发病在我国呈明显增高趋势,逐渐成为我国常见的消化系疾病。随着我国医生和医学研究者对该病关注度的增高,十多年来我国在IBD的诊断和治疗技术上已有很大提高,但在改善对IBD患者的健康服务方面尚缺乏足够关注,与西方发达国家存在很大差距。
出处 《中华内科杂志》 CAS CSCD 北大核心 2016年第7期568-571,共4页 Chinese Journal of Internal Medicine
  • 相关文献

参考文献7

  • 1Ng SC. Epidemiology of inflammatory bowel disease : focus on Asia [ J ]. Best Pract Res Clin Gastroenterol, 2014,28 ( 3 ) : 363-372. DOI : 10. 1016/j. bpg. 2014.04. 003.
  • 2Pan6s J, O'Connor M, Peyrin-Biroulet L, et al. Improving quality of care in inflammatory bowel disease: what changes can be made today.'? [J]. J Crohns Colitis, 2014,8(9):919-926. DOI: 10. 1016/j. crohns. 2014.02. 022.
  • 3Fitch K, Bernstein S, Aguilar MS, et al. The RAND/UCLA appropriateness method user's manual [ M ]. Santa Moniea, CA: RAND ,2001.
  • 4The IBD Standards Group. Quality care: service standards for the healthcare of people who have inflammatory bowel disease ( IBD ) [ S/OL]. [ 2016-03-01 ]. http ://www. ibdstandards, org. uk/.
  • 5Calvet X, Pan6s J, Alfaro N, et al. Delphi consensus statement: quality indicators for inflammatory bowel disease comprehensive care units[J]. J Crohns Colitis, 2014,8(3) :240-251. DOI: 10. 1016/j. crohns. 2013.10. 010.
  • 6Melmed GY, Siegel CA, Spiegel BM, et al. Quality indicators for inflammatory bowel disease: development of process and outcome measures[ J]. Inflamm Bowel Dis, 2013,19 (3) :662-668. DOI: 10.1097/mib. 0b013e31828278a2.
  • 7张芳宾,丁亮,高翔,刘慧,肖英莲,陈旻湖,黄民,胡品津.硫嘌呤甲基转移酶基因型和酶活性检测在炎症性肠病治疗中的临床价值[J].中华消化杂志,2010,30(7):436-440. 被引量:21

二级参考文献16

  • 1吴珏珩,黄民,张建萍,张选红,汤丽芬.中国健康汉族和瑶族人群巯基嘌呤甲基转移酶活性的分布[J].中国临床药理学杂志,2005,21(4):260-263. 被引量:2
  • 2詹钟平,杨岫岩,梁柳琴,王一西,黄民,连帆.风湿病患者硫唑嘌呤代谢酶活性分布及其临床意义[J].中华内科杂志,2006,45(7):537-539. 被引量:5
  • 3郑家驹,褚行琦,史肖华,周春立,王毓明.硫唑嘌呤维持克罗恩病临床缓解的疗效与安全性[J].中华消化杂志,2007,27(5):299-302. 被引量:6
  • 4詹钟平,梁柳琴,杨岫岩,王一西,黄民,李昊.风湿病人群硫唑嘌呤代谢酶基因型与药物耐受性的关系[J].中华医学杂志,2007,87(25):1734-1737. 被引量:4
  • 5Travis SP,Stange EF.Lémann M,et al,European evidence based consensus on the diagnosis and management of Crohn' s disease:current management.Gut,2006,55 Suppl 1,i16-i35.
  • 6Ansari A,Arenas M,Greenfield SM,et al.Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.Aliment Pharmacol Ther,2008,28:973-983.
  • 7Gisbert JP,Ni(n)o P,Rodrigo L,et al.Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease:long-term follow-up study of 394 patients.Am J Gastroenterol,2006,101:2769-2776.
  • 8Schaeffeler E,Fischer C,Brockmeier D,et al.Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants.Pharmacogenetics,2004,14:407-417.
  • 9Hindorf U,Lindqvist M,Hildebrand H,et al.Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.Aliment Pharmacol Ther,2006,24:331-342.
  • 10Derijks LJ,Gilissen LP,Hooymans PM,et al.Revie warticle:thiopurines in inflammatory bowel disease.Aliment Pharmacol Ther,2006,24:715-729.

共引文献20

同被引文献101

引证文献15

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部